Acetic Acid Mediated for One-Pot Synthesis of Novel Pyrazolyl -Triazine Derivatives for the Targeted Therapy of Triple-Negative Breast Tumor Cells (MDA-MB-231) EGFR/PI3K/AKT/mTOR Signaling Cascades.

Here, we described the synthesis of novel pyrazole--triazine derivatives via an easy one-pot procedure for the reaction of β-dicarbonyl compounds (ethylacetoacetate, 5,5-dimethyl-1,3-cyclohexadione or 1,3-cyclohexadionone) with ,-dimethylformamide dimethylacetal, followed by addition of 2-hydrazinyl-4,6-disubstituted--triazine either in ethanol-acetic acid or neat acetic acid to afford a novel pyrazole and pyrazole-fused cycloalkanone systems. The synthetic protocol proved to be efficient, with a shorter reaction time and high chemical yield with broad substrates. The new pyrazolyl--triazine derivatives were tested against the following cell lines: MCF-7 (breast cancer); MDA-MB-231 (triple-negative breast cancer); U-87 MG (glioblastoma); A549 (non-small cell lung cancer); PANC-1 (pancreatic cancer); and human dermal fibroblasts (HDFs). The cell viability assay revealed that most of the -triazine compounds induced cytotoxicity in all the cell lines tested. However, compounds , and , which all have a piperidine or morpholine moiety with one aniline ring or two aniline rings in their structures, were the most effective. Compounds and showed potent EGFR inhibitory activity with IC values of 59.24 and 70.3 nM, respectively, compared to Tamoxifen (IC value of 69.1 nM). Compound exhibited moderate activity, with IC values of 81.6 nM. Interestingly, hybrids and exerted remarkable PI3K/AKT/mTOR inhibitory activity with 0.66/0.82/0.80 and 0.35/0.56/0.66-fold, respectively, by inhibiting their concentrations to 4.39, 37.3, and 69.3 ng/mL in the -treatment, and to 2.39, 25.34 and 57.6 ng/mL in the -treatment compared to the untreated control.